BRAF and melanoma: This is supported by a recent study showing that intermittent dosing of patient-derived xenografts of BRAF V600E mutant melanoma results in a failure to reach lethal drug resistance, even when the cumulative dose meets or exceeds that received on a continuous dosing regimen where all tumors acquired lethal drug resistance [72].